Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
